CO6592093A2 - Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina - Google Patents

Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina

Info

Publication number
CO6592093A2
CO6592093A2 CO12151303A CO12151303A CO6592093A2 CO 6592093 A2 CO6592093 A2 CO 6592093A2 CO 12151303 A CO12151303 A CO 12151303A CO 12151303 A CO12151303 A CO 12151303A CO 6592093 A2 CO6592093 A2 CO 6592093A2
Authority
CO
Colombia
Prior art keywords
naphthalenyl
polymorphs
pyrazol
solvates
methyl
Prior art date
Application number
CO12151303A
Other languages
English (en)
Inventor
Maimo Ramon Berenguer
Ruperez Jorge Medrano
Fernandez Laura Puig
Buchholz Jordi Benet
Puxeu Laia Pelleja
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10382025A external-priority patent/EP2361904A1/en
Priority claimed from EP10382226A external-priority patent/EP2426112A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of CO6592093A2 publication Critical patent/CO6592093A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polimorfos y solvatos del clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etii]morfolina (P027) como antagonistas del receptor sigma-l útiles en el tratamiento y prevención del dolor crónico o agudo, procedimientos para su obtención, y composiciones farmacéuticas que los comprenden.
CO12151303A 2010-02-04 2012-09-04 Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina CO6592093A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382025A EP2361904A1 (en) 2010-02-04 2010-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP10382226A EP2426112A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Publications (1)

Publication Number Publication Date
CO6592093A2 true CO6592093A2 (es) 2013-01-02

Family

ID=43897079

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12151303A CO6592093A2 (es) 2010-02-04 2012-09-04 Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina

Country Status (31)

Country Link
US (2) USRE47214E1 (es)
EP (1) EP2531177B8 (es)
JP (1) JP5894086B2 (es)
KR (2) KR20120123532A (es)
CN (1) CN102753155B (es)
AR (1) AR080133A1 (es)
AU (1) AU2011212476B2 (es)
BR (1) BR112012018958A8 (es)
CA (1) CA2788024C (es)
CO (1) CO6592093A2 (es)
CY (1) CY1117886T1 (es)
DK (1) DK2531177T3 (es)
EC (1) ECSP12012039A (es)
ES (1) ES2586212T3 (es)
HR (1) HRP20160937T1 (es)
HU (1) HUE029738T2 (es)
IL (1) IL221277A (es)
MA (1) MA34047B1 (es)
ME (1) ME02483B (es)
MX (1) MX339193B (es)
NZ (1) NZ601316A (es)
PL (1) PL2531177T3 (es)
PT (1) PT2531177T (es)
RS (1) RS55046B1 (es)
RU (1) RU2560150C2 (es)
SG (2) SG182628A1 (es)
SI (1) SI2531177T1 (es)
SM (1) SMT201600264B (es)
TN (1) TN2012000347A1 (es)
TW (1) TWI568729B (es)
WO (1) WO2011095579A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
TN2016000229A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr Gabapentinoids and sigma receptor ligands combinations.
WO2017211763A1 (en) 2016-06-06 2017-12-14 Laboratorios Del Dr. Esteve, S.A. Use of sigma receptor ligands in cancer
TW201806601A (zh) 2016-07-12 2018-03-01 以斯提夫博士實驗室股份有限公司 σ受體配體在皰疹後遺疼痛中的用途
WO2018059420A1 (zh) * 2016-09-27 2018-04-05 苏州科睿思制药有限公司 E52862盐酸盐晶型h及其制备方法
WO2019068771A1 (en) 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS
KR20220123634A (ko) 2019-10-31 2022-09-08 이스케이프 바이오, 인크. S1p-수용체 조절제의 고체 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
CA2576144C (en) * 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
CA2641144A1 (en) * 2006-03-01 2007-09-07 Rosa Cuberes-Altisent Pyrazole derivatives as sigma receptor inhibitors
US7695199B2 (en) 2006-07-20 2010-04-13 Finisar Corporation Optical subassembly having insertable cylindrical sleeve
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors

Also Published As

Publication number Publication date
RU2012137495A (ru) 2014-03-10
US20120316336A1 (en) 2012-12-13
EP2531177B1 (en) 2016-05-11
IL221277A (en) 2017-06-29
PL2531177T3 (pl) 2016-11-30
JP5894086B2 (ja) 2016-03-23
IL221277A0 (en) 2012-10-31
CY1117886T1 (el) 2017-05-17
CN102753155B (zh) 2015-11-25
SG182628A1 (en) 2012-08-30
MX339193B (es) 2016-05-16
BR112012018958A2 (pt) 2016-04-12
MA34047B1 (fr) 2013-03-05
SI2531177T1 (sl) 2016-10-28
SMT201600264B (it) 2016-08-31
US9051275B2 (en) 2015-06-09
HUE029738T2 (en) 2017-04-28
JP2013518857A (ja) 2013-05-23
CN102753155A (zh) 2012-10-24
NZ601316A (en) 2013-12-20
EP2531177A1 (en) 2012-12-12
KR20120123532A (ko) 2012-11-08
WO2011095579A1 (en) 2011-08-11
ME02483B (me) 2017-02-20
AU2011212476B2 (en) 2016-03-31
TN2012000347A1 (en) 2014-01-30
RS55046B1 (sr) 2016-12-30
AR080133A1 (es) 2012-03-14
BR112012018958A8 (pt) 2017-12-19
KR20180063379A (ko) 2018-06-11
USRE47214E1 (en) 2019-01-29
ECSP12012039A (es) 2012-08-31
HRP20160937T1 (hr) 2016-10-07
RU2560150C2 (ru) 2015-08-20
TW201136923A (en) 2011-11-01
DK2531177T3 (en) 2016-08-22
TWI568729B (zh) 2017-02-01
CA2788024A1 (en) 2011-08-11
SG10201500832PA (en) 2015-04-29
MX2012009018A (es) 2012-09-07
PT2531177T (pt) 2016-08-17
CA2788024C (en) 2018-03-13
AU2011212476A1 (en) 2012-08-09
EP2531177B8 (en) 2016-10-12
ES2586212T3 (es) 2016-10-13

Similar Documents

Publication Publication Date Title
CO6592093A2 (es) Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CO6400220A2 (es) Derivados de sulfonamida
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
DOP2012000006A (es) Agonista de gpr119
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
UY32848A (es) Compuestos heterocíclicos de oxima
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
CL2017000432A1 (es) Inhibidores espirocíclicos de catepsina c
TN2012000247A1 (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
CL2012002739A1 (es) Compuesto (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida; composicion farmaceutica que lo comprende; uso del compuesto para el tratamiento de migraña, dolor neuropático, cancer de mama y glioma.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CR9722A (es) Derivados de benzilpiperazina y su uso medico
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CL2008001261A1 (es) Compuestos derivados de 4-(benzoxanol-2-ilamino), ligandos del receptor npy y5; composiciones farmaceuticas que los contienen; y sus uso en la preparacion de medicamentos utiles en el tratamiento de la depresion, la ansiedad o la obesidad.

Legal Events

Date Code Title Description
FC Application refused